Alterity醫療 ATHE 深 滬
已收盤 01-30 16:00:00 美东时间
3.17
-0.090
-2.76%
華盛通- 最 高3.2486
- 今 開3.16
- 成交量 1.45万股
- 最 低 3.07
- 昨 收 3.26
- 總市值 5745.85万
- 52周最高 7.00
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 2.5209
- 委 比 -10.77%
- 總股本 1812.57万
- 歷史最高 51.50
- 量 比 0.51
- 振 幅 5.48%
- 歷史最低 1.001
- 每 手 1
- 風險率 0.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics provided an update on its activities for Q2 FY26, highlighting advancements in its MSA program, Phase 2 data strengthening, and planning for a pivotal Phase 3 trial. The company presented additional analyses of the Phase 2 trial at international congresses, including improved efficacy signals for ATH434 at the 75 mg dose. Regulatory planning for an End-of-Phase 2 meeting with the FDA in mid-2026 is progressing, with a focus ...
01-30 12:25
Alterity Targets $2.4B Market as Lead Drug Clears Phase 2 and Moves Toward Phase 3
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to
01-21 20:27
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
Alterity Therapeutics (ATH) achieved Phase 2 success for ATH434 in treating Multiple System Atrophy (MSA), demonstrating safety, efficacy, and disease progression slowing. Results position the company for Phase 3 planning and potential entry into a $2.4B market. Key 2026 milestones include FDA-end-of-Phase 2 meeting, expanding engagement, and scaling infrastructure. The company also strengthened its leadership team to support growth. Alterity rem...
01-21 12:25
Alterity Flags Risk Context for Forward-Looking Statements in 2026 Presentation
The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alteri...
01-13 08:18
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers MoonLake (NASDAQ:MLTX) stock rose 8.2% to $20.0 during Friday's after-...
01-10 05:05
Alterity Therapeutics Announces Director Departure
The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alteri...
2025-11-24 11:28
Alterity Therapeutics CEO Outlines Strategic Vision
Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeut...
2025-11-21 09:07
Alterity Therapeutics Advances in Neurodegenerative Disease Treatment
Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics...
2025-11-21 08:57
Alterity Therapeutics Announces Board Restructuring for Growth
An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alte...
2025-11-21 07:28
Alterity Therapeutics Discloses Equity Derivative Positions
The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alteri...
2025-11-13 12:48
